doi:10.3760/cma.j.cn371439-20201015-00095

Abstract

Figures/Tables 11

References 69

[1]	NCCN Clinical Practice Guidelines in Oncology: Esophageal and Esophagogastric Junction Cancers, Version 3. 2020[EB/OL]. [2020-07-31]. https://www.nccn.org/.
[2]	He Y, Li D, Shan B, et al. Incidence and mortality of esophagus cancer in China, 2008-2012[J]. Chin J Cancer Res, 2019,31(3):426-434. DOI: 10.21147/j.issn.1000-9604.2019.03.04. doi: 10.21147/j.issn.1000-9604.2019.03.04 pmid: 31354211
[3]	中国抗癌协会食管癌专业委员会. 食管癌规范化诊治指南[M]. 北京: 中国协和医科大学出版社, 2011.
[4]	Gibault L, Metges JP, Conan-Charlet V, et al. Diffuse EGFR staining is associated with reduced overall survival in locally advanced oeso-phageal squamous cell cancer[J]. Br J Cancer, 2005,93(1):107-115. DOI: 10.1038/sj.bjc.6602625. doi: 10.1038/sj.bjc.6602625 pmid: 15986037
[5]	Tsutsumi S, Saeki H, Nakashima Y, et al. Programmed death-ligand 1 expression at tumor invasive front is associated with epithelial-mesenchymal transition and poor prognosis in esophageal squamous cell carcinoma[J]. Cancer Sci, 2017,108(6):1119-1127. DOI: 10.1111/cas.13237. doi: 10.1111/cas.13237 pmid: 28294486
[6]	Bunting D, Bracey T, Fox B, et al. Loco-regional staging accuracy in esophageal cancer—How good are we in the modern era?[J]. Eur J Radiol, 2017,97(1):71-75. DOI: 10.1016/j.ejrad.2017.10.015. doi: 10.1016/j.ejrad.2017.10.015
[7]	eL-Khoury GY, Dalinka MK, Alazraki N, Metastatic bone disease. American College of Radiology[J]. Appropriateness Criteria, 2000,215 Suppl: 283-293.
[8]	Minashi K, Nihei K, Mizusawa J, et al. Efficacy of endoscopic resection and selective chemoradiotherapy for stage Ⅰ esophageal squamous cell carcinoma[J]. Gastroenterology, 2019, 157(2):382-390. DOI: 10.1053/j.gastro.2019.04.017. doi: 10.1053/j.gastro.2019.04.017 pmid: 31014996
[9]	Kato H, Sato A, Fukuda H, et al. A Phase Ⅱ trial of chemoradiotherapy for stage Ⅰ esophageal squamous cell carcinoma: Japan Clinical Oncology Group Study (JCOG9708)[J]. Jpn J Clin Oncol, 2009,39(10):638-643. DOI: 10.1093/jjco/hyp069. doi: 10.1093/jjco/hyp069 pmid: 19549720
[10]	Juloori A, Tucker SL, Komaki R, et al. Influence of preoperative radiation field on postoperative leak rates in esophageal cancer patients after trimodality therapy[J]. J Thorac Oncol, 2014,9(4):534-540. DOI: 10.1097/JTO.0000000000000100. doi: 10.1097/JTO.0000000000000100
[11]	Huang W, Huang Y, Sun J, et al. Atlas of the thoracic lymph nodal delineation and recommendations for lymph nodal CTV of esophageal squamous cell cancer in radiation therapy from China[J]. Radiother Oncol, 2015,116(1):100-106. DOI: 10.1016/j.radonc.2015.06.024. doi: 10.1016/j.radonc.2015.06.024 pmid: 26142269
[12]	Huang W, Li B, Gong H, et al. Pattern of lymph node metastases and its implication in radiotherapeutic clinical target volume in patients with thoracic esophageal squamous cell carcinoma: a report of 1077 cases[J]. Radiother Oncol, 2010,95(2):229-233. DOI: 10.1016/j.radonc.2010.01.006. doi: 10.1016/j.radonc.2010.01.006 pmid: 20189259
[13]	Cheng J, Kong L, Huang W, et al. Explore the radiotherapeutic clinical target volume delineation for thoracic esophageal squamous cell carcinoma from the pattern of lymphatic metastases[J]. J Thorac Oncol, 2013,8(3):359-365. DOI: 10.1097/JTO.0b013e31827e1f6d. doi: 10.1097/JTO.0b013e31827e1f6d pmid: 23263689
[14]	Ding X, Zhang J, Li B, et al. A meta-analysis of lymph node metastasis rate for patients with thoracic oesophageal cancer and its implication in delineation of clinical target volume for radiation therapy[J]. Br J Radiol, 2012,85(1019):e1110-e1119. DOI: 10.1259/bjr/12500248. pmid: 22700258
[15]	Dong Y, Guan H, Huang W, et al. Precise delineation of clinical target volume for crossing-segments thoracic esophageal squamous cell carcinoma based on the pattern of lymph node metastases[J]. J Thorac Dis, 2015,7(12):2313-2320. DOI: 10.3978/j.issn.2072-1439.2015.12.10. doi: 10.3978/j.issn.2072-1439.2015.12.10 pmid: 26793353
[16]	Shapiro J, van Lanschot JJB, Hulshof MCCM, et al. Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial[J]. Lancet Oncol, 2015,16(9):1090-1098. DOI: 10.1016/S1470-2045(15)00040-6. doi: 10.1016/S1470-2045(15)00040-6 pmid: 26254683
[17]	van Hagen P, Hulshof MC, van Lanschot JJ, et al. Preoperative chemoradiotherapy for esophageal or junctional cancer[J]. N Engl J Med, 2012,366(22):2074-2084. DOI: 10.1056/NEJMoa1112088. doi: 10.1056/NEJMoa1112088 pmid: 22646630
[18]	王玉祥, 杨琼, 何明, 等. Ⅲ期胸段食管鳞癌根治术后的复发规律[J]. 中华肿瘤杂志, 2017,39(1):48-55. DOI: 10.3760/cma.j.issn.0253-3766.2017.01.010.
[19]	Chapet O, Kong FM, Quint LE, et al. CT-based definition of thoracic lymph node stations: an atlas from the University of Michigan[J]. Int J Radiat Oncol Biol Phys, 2005,63(1):170-178. DOI: 10.1016/j.ijrobp.2004.12.060. doi: 10.1016/j.ijrobp.2004.12.060 pmid: 16111586
[20]	Liu Q, Cai XW, Wu B, et al. Patterns of failure after radical sur-gery among patients with thoracic esophageal squamous cell carcinoma: implications for the clinical target volume design of postoperative radiotherapy[J]. PLoS One, 2014,9(5):e97225. DOI: 10.1371/journal.pone.0097225. doi: 10.1371/journal.pone.0097225 pmid: 24820177
[21]	Wong AT, Shao M, Rineer J, et al. The impact of adjuvant post-operative radiation therapy and chemotherapy on survival after esophagectomy for esophageal carcinoma[J]. Ann Surg, 2017,265(6):1146-1151. DOI: 10.1097/SLA.0000000000001825. doi: 10.1097/SLA.0000000000001825 pmid: 27280504
[22]	Xiao ZF, Yang ZY, Liang J, et al. Value of radiotherapy after radical surgery for esophageal carcinoma: a report of 495 patients[J]. Ann Thorac Surg, 2003,75(2):331-336. DOI: 10.1016/s0003-4975(02)04401-6. doi: 10.1016/s0003-4975(02)04401-6 pmid: 12607634
[23]	Worni M, Martin J, Gloor B, et al. Does surgery improve outcomes for esophageal squamous cell carcinoma? An analysis using the surveillance epidemiology and end results registry from 1998 to 2008[J]. J Am Coll Surg, 2012,215(5):643-651. DOI: 10.1016/j.jamcollsurg.2012.07.006. doi: 10.1016/j.jamcollsurg.2012.07.006 pmid: 23084493
[24]	Chen J, Zhu J, Pan J, et al. Postoperative radiotherapy improved survival of poor prognostic squamous cell carcinoma esophagus[J]. Ann Thorac Surg, 2010,90(2):435-442. DOI: 10.1016/j.athoracsur.2010.04.002. doi: 10.1016/j.athoracsur.2010.04.002
[25]	Schreiber D, Rineer J, Vongtama D, et al. Impact of postoperative radiation after esophagectomy for esophageal cancer[J]. J Thorac Oncol, 2010,5(2):244-250. DOI: 10.1097/JTO.0b013e3181c5e34f. doi: 10.1097/JTO.0b013e3181c5e34f pmid: 20009774
[26]	Shridhar R, Weber J, Hoffe SE, et al. Adjuvant radiation therapy and lymphadenectomy in esophageal cancer: a SEER database analysis[J]. J Gastrointest Surg, 2013,17(8):1339-1345. DOI: 10.1007/s11605-013-2192-7. doi: 10.1007/s11605-013-2192-7
[27]	Xu Y, Liu J, Du X, et al. Prognostic impact of postoperative radi-ation in patients undergoing radical esophagectomy for pathologic lymph node positive esophageal cancer[J]. Radiat Oncol, 2013,8:116. DOI: 10.1186/1748-717X-8-116. doi: 10.1186/1748-717X-8-116 pmid: 23656920
[28]	Zhang W, Liu X, Xiao Z, et al. Postoperative intensity-modulated radiotherapy improved survival in lymph node-positive or stage Ⅲ thoracic esophageal squamous cell carcinoma[J]. Oncol Res Treat, 2015,38(3):97-102. DOI: 10.1159/000375391. doi: 10.1159/000375391 pmid: 25792080
[29]	Chen SB, Weng HR, Wang G, et al. The impact of adjuvant radiotherapy on radically resected T₃ esophageal squamous cell carcinoma[J]. J Cancer Res Clin Oncol, 2016,142(1):277-286. DOI: 10.1007/s00432-015-2041-z. doi: 10.1007/s00432-015-2041-z pmid: 26328915
[30]	刘晓, 章文成, 于舒飞, 等. T_2-3N₀M₀期食管癌R0术后失败模式分析——术后放疗潜在价值与意义[J]. 中华放射肿瘤学杂志, 2015,24(1):19-24. DOI: 10.3760/cma.j.issn.1004-4221.2015.01.006. doi: 10.3760/cma.j.issn.1004-4221.2015.01.006
[31]	Yang J, Zhang W, Xiao Z, et al. The impact of postoperative conformal radiotherapy after radical surgery on survival and recurrence in pathologic T₃N₀M₀ esophageal carcinoma: a propensity score-matched analysis[J]. J Thorac Oncol, 2017,12(7):1143-1151. DOI: 10.1016/j.jtho.2017.03.024. doi: 10.1016/j.jtho.2017.03.024 pmid: 28411098
[32]	Kirkpatrick JP, van der Kogel AJ, Schultheiss TE. Radiation dose-volume effects in the spinal cord[J]. Int J Radiat Oncol Biol Phys, 2010,76(3 Suppl):S42-S49. DOI: 10.1016/j.ijrobp.2009.04.095. doi: 10.1016/j.ijrobp.2009.04.095 pmid: 20171517
[33]	Marks LB, Yorke ED, Jackson A, et al. Use of normal tissue complication probability models in the clinic[J]. Int J Radiat Oncol Biol Phys, 2010,76(3 Suppl):S10-S19. DOI: 10.1016/j.ijrobp.2009.07.1754. doi: 10.1016/j.ijrobp.2009.07.1754 pmid: 20171502
[34]	Mizumoto M, Sugahara S, Nakayama H, et al. Clinical results of proton-beam therapy for locoregionally advanced esophageal cancer[J]. Strahlenther Onkol, 2010,186(9):482-488. DOI: 10.1007/s00066-010-2079-4. doi: 10.1007/s00066-010-2079-4
[35]	Xi M, Xu C, Liao Z, et al. Comparative outcomes after definitive chemoradiotherapy using proton beam therapy versus intensity modulated radiation therapy for esophageal cancer: a retrospective, single-institutional analysis[J]. Int J Radiat Oncol Biol Phys, 2017,99(3):667-676. DOI: 10.1016/j.ijrobp.2017.06.2450. doi: 10.1016/j.ijrobp.2017.06.2450 pmid: 29280461
[36]	Fernandes A, Berman AT, Mick RA, et al. Prospective study of proton beam reirradiation for esophageal cancer[J]. Int J Radiat Oncol Biol Phys, 2016,95(1):483-487. DOI: 10.1016/j.ijrobp.2015.12.005. doi: 10.1016/j.ijrobp.2015.12.005 pmid: 26847847
[37]	Routman DM, Garant A, Lester SC, et al. A comparison of grade 4 lymphopenia with proton versus photon radiation therapy for esophageal cancer[J]. Adv Radiat Oncol, 2019,4(1):63-69. DOI: 10.1016/j.adro.2018.09.004. doi: 10.1016/j.adro.2018.09.004 pmid: 30706012
[38]	Akutsu Y, Yasuda S, Nagata M, et al. A phase Ⅰ/Ⅱ clinical trial of preoperative short-course carbon-ion radiotherapy for patients with squamous cell carcinoma of the esophagus[J]. J Surg Oncol, 2012,105(8):750-755. DOI: 10.1002/jso.22127. doi: 10.1002/jso.22127 pmid: 22012645
[39]	Zhu L, Jiang Y, Wang J, et al. An investigation of ¹²⁵I seed permanent implantation for recurrent carcinoma in the head and neck after surgery and external beam radiotherapy[J]. World J Surg Oncol, 2013,11:60. DOI: 10.1186/1477-7819-11-60. doi: 10.1186/1477-7819-11-60 pmid: 23496973
[40]	Zhu HD, Guo JH, Mao AW, et al. Conventional stents versus stents loaded with 125iodine seeds for the treatment of unresectable oeso-phageal cancer: a multicentre, randomized phase 3 trial[J]. Lancet Oncol, 2014 , 15(6):612-619. DOI: 10.1016/S1470-2045(14)70131-7. doi: 10.1016/S1470-2045(14)70131-7
[41]	Cooper JS, Guo MD, Herskovic A, et al. Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85-01). Radiation Therapy Oncology Group[J]. JAMA, 1999,281(17):1623-1627. DOI: 10.1001/jama.281.17.1623. doi: 10.1001/jama.281.17.1623 pmid: 10235156
[42]	Noordman BJ, Spaander MCW, Valkema R, et al. Detection of residual disease after neoadjuvant chemoradiotherapy for oesophageal cancer (preSANO): a prospective multicenter, diagnostic cohort study[J]. Lancet Oncol, 2018,19(7):965-974. DOI: 10.1016/S1470-2045(18)30201-8. doi: 10.1016/S1470-2045(18)30201-8 pmid: 29861116
[43]	Noordman BJ, Wijnhoven BPL, Lagarde SM, et al. Neoadjuvant chemoradiotherapy plus surgery versus active surveillance for oeso-phageal cancer: a stepped-wedge cluster randomised trial[J]. BMC Cancer, 2018,18(1):142. DOI: 10.1186/s12885-018-4034-1. doi: 10.1186/s12885-018-4034-1 pmid: 29409469
[44]	Wainberg ZA, Lin LS, DiCarlo B, et al. Phase Ⅱ trial of modified FOLFOX6 and erlotinib in patients with metastatic or advanced adenocarcinoma of the oesophagus and gastro-oesophageal junction[J]. Br J Cancer, 2011,105(6):760-765. DOI: 10.1038/bjc.2011.280. doi: 10.1038/bjc.2011.280 pmid: 21811258
[45]	Doi T, Piha-Paul SA, Jalal S, et al. Safety and antitumor activity of the anti-programmed death-1 antibody pembrolizumab in patients with advanced esophageal carcinoma[J]. J Clin Oncol, 2018,36(1):61-67. DOI: 10.1200/JCO.2017.74.9846. doi: 10.1200/JCO.2017.74.9846 pmid: 29116900
[46]	Kudo T, Hamamoto Y, Kato K, et al. Nivolumab treatment for oesophageal squamous-cell carcinoma: an open-label, multicentre, phase 2 trial[J]. Lancet Oncol, 2017,18(5):631-639. DOI: 10.1016/S1470-2045(17)30181-X. doi: 10.1016/S1470-2045(17)30181-X pmid: 28314688
[47]	Huang J, Xu B, Mo H, et al. Safety, activity, and biomarkers of SHR-1210, an anti-PD-1 antibody, for patients with advanced esophageal carcinoma[J]. Clin Cancer Res, 2018,24(6):1296-1304. DOI: 10.1158/1078-0432.CCR-17-2439. doi: 10.1158/1078-0432.CCR-17-2439 pmid: 29358502
[48]	Janjigian YY, Bendell J, Calvo E, et al. Checkmate-032 study: efficacy and safety of nivolumab and nivolmab plus ipilimumab in patients with metastatic esophagogastric cancer[J]. J Clin Oncol, 2018,36(28):2836-2844. DOI: 10.1200/JCO.2017.76.6212. doi: 10.1200/JCO.2017.76.6212 pmid: 30110194
[49]	Alsina M, Moehler M, Lorenzen S. Immunotherapy of esophageal cancer: current status, many trials and innovative strategies[J]. Oncol Res Treat, 2018,41(5):266-271. DOI: 10.1159/000488120. doi: 10.1159/000488120 pmid: 29705786
[50]	Meindl-Beinker NM, Betge J, Gutting T, et al. A multicenter open-label phase Ⅱ trial to evaluate nivolumab and ipilimumab for 2nd line therapy in elderly patients with advanced esophageal squamous cell cancer (RAMONA)[J]. BMC Cancer, 2019,19(1):231. DOI: 10.1186/s12885-019-5446-2. doi: 10.1186/s12885-019-5446-2 pmid: 30871493
[51]	Ralph C, Elkord E, Burt DJ, et al. Modulation of lymphocyte regulation for cancer therapy: a phase Ⅱ trial of tremelimumab in advanced gastric and esophageal adenocarcinoma[J]. Clin Cancer Res, 2010,16(5):1662-1672. DOI: 10.1158/1078-0432.CCR-09-2870. doi: 10.1158/1078-0432.CCR-09-2870 pmid: 20179239
[52]	FDA Approves New Monotherapy Indication for Merck̓s KEYTRUDA? (pembrolizumab)[EB/OL]. [2019-07-31]. https://www.mrknewsroom.com/news-release/prescription-medicine-news/fda-approves-new-monotherapy-indication-mercks-keytruda-pemb.
[53]	Wang H, Mu X, He H, et al. Cancer radiosensitizers[J]. Trends Pharmacol Sci, 2018,39(1):24-48. DOI: 10.1016/j.tips.2017.11.003. doi: 10.1016/j.tips.2017.11.003 pmid: 29224916
[54]	康梅, 权循凤. 食管癌放疗增敏剂的临床研究[J]. 国际肿瘤学杂志, 2015,42(12):932-935. DOI: 10.3760/cma.j.issn.1673-422X.2015.12.013. doi: 10.3760/cma.j.issn.1673-422X.2015.12.013
[55]	邓家营, 王春雨, 赵快乐. 紫杉醇(PTX)在食管癌同期放化疗中的研究进展[J]. 复旦学报(医学版), 2014,41(5):697-700. DOI: 10.3969/j.issn.1672-8467.2014.05.023.
[56]	Ruhstaller T, Pless M, Dietrich D, et al. Cetuximab in combination with chemoradiotherapy before surgery in patients with resectable, locally advanced esophageal carcinoma: a prospective, multicenter phase ⅠB/Ⅱ trial (SAKK 75/06)[J]. J Clin Oncol, 2011,29(6):626-631. DOI: 10.1200/JCO.2010.31.9715. doi: 10.1200/JCO.2010.31.9715
[57]	Li W, Chen P, Zhang N, et al. Endostatin and oxaliplatin-based chemoradiotherapy for inoperable esophageal squamous cell carcinoma: results of a phase Ⅱ study[J]. Oncologist, 2019,24(4):461-e136. DOI: 10.1634/theoncologist.2019-0119. doi: 10.1634/theoncologist.2019-0119 pmid: 30850562
[58]	Wilke H, Muro K, Van Cutsem E, et al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial[J]. Lancet Oncol, 2014,15(11):1224-1235. DOI: 10.1016/S1470-2045(14)70420-6. doi: 10.1016/S1470-2045(14)70420-6
[59]	秦尚彬, 王雅棣, 杨俊泉, 等. 甘氨双唑钠胸段食管鳞癌放射增敏作用——Ⅲ期多中心随机对照研究[J]. 中华放射肿瘤学杂志, 2012,21(5):426-429. DOI: 10.3760/cma.j.issn.1004-4221.2012.05.009.
[60]	Steward WP, Middleton M, Benghiat A, et al. The use of pharmacokinetic and pharmacodynamic end points to determine the dose of AQ4N, a novel hypoxic cell cytotoxin, given with fractionated radiotherapy in a phase Ⅰ study[J]. Ann Oncol, 2007,18(6):1098-1103. DOI: 10.1093/annonc/mdm120. doi: 10.1093/annonc/mdm120 pmid: 17442658
[61]	龚林吉, 谢佳妮, 朱双, 等. 多功能纳米材料在肿瘤放疗增敏中的应用[J]. 物理化学学报, 2018,34(2):140-167. DOI: 10.3866/PKU.WHXB201707174.
[62]	吕家华, 李涛. 食管癌放疗患者的营养治疗[J]. 肿瘤代谢与营养电子杂志, 2017,4(2):144-148. DOI: 10.16689/j.cnki.cn11-9349/r.2017.02.003.
[63]	Lyu J, Li T, Xie CH, et al. Enteral nutrition in esophageal cancer patients treated with radiotherapy: a Chinese expert consensus 2018[J]. Future Oncol, 2019,15(5):517-531. DOI: 10.2217/fon-2018-0697.
[64]	Xu YJ, Cheng JC, Lee JM, et al. A walk-and-eat intervention improves outcomes for patients with esophageal cancer undergoing neoadjuvant chemoradiotherapy[J]. Oncologist, 2015,20(10):1216-1222. DOI: 10.1634/theoncologist.2015-0178. doi: 10.1634/theoncologist.2015-0178 pmid: 26341759
[65]	吕家华, 李涛, 朱广迎, 等. 肠内营养对食管癌同步放化疗患者营养状况、不良反应和近期疗效影响——前瞻性、多中心、随机对照临床研究(NCT02399306)[J]. 中华放射肿瘤学杂志, 2018,27(1):44-48. DOI: 10.3760/cma.j.issn.1004-4221.2018.01.009.
[66]	Fietkau R, Lewitzki V, Kuhnt T, et al. A disease-specific enteral nutrition formula improves nutritional status and functional perfor-mance in patients with head and neck and esophageal cancer undergoing chemoradiotherapy: results of a randomized, controlled, multicenter trial[J]. Cancer, 2013,119(18):3343-3353. DOI: 10.1002/cncr.28197. doi: 10.1002/cncr.28197 pmid: 23765693
[67]	Checkmate -649, a phase 3 trial evaluating opdivo (nivolumab) plus chemotherapy vs. chemotherapy, meets primary endpoints demonstrating superior overall survival and progression-free survival in first-line treatment of gastric and esophageal cancers[EB/OL].[2020-08-11]. https://news.bms.com/press-release/corporatefinancial-news/checkmate-649-phase-3-trial-evaluating-opdivo-nivolumab-plus-c.
[68]	Merck̓s KEYTRUDA^® (pembrolizumab) in combination with chemotherapy significantly improved overall survival and progression-free survival compared with chemotherapy in locally advanced or first-line metastatic esophageal cancer[EB/OL].[2020-08-19]. https://www.merck.com/news/mercks-keytruda-pembrolizumab-in-combination-with-chemotherapy-significantly-improved-overall-survi-val-and-progression-free-survival-compared-with-chemotherapy-in-locally-advanced-or/.
[69]	Opdivo (nivolumab) demonstrated superior disease-free survival in patients with resected esophageal or gastroesophageal junction cancer compared to placebo in the adjuvant setting[EB/OL].[2020-09-21]. https://news.bms.com/news/details/2020/Opdivo-nivolumab-Demonstrated-Superior-Disease-Free-Survival-in-Patients-with-Resected-Esophageal-or-Gastroesophageal-Junction-Cancer-Compared-to-Placebo-in-the-Adjuvant-Setting/default.aspx.

	N₀	N₁	N₂	N₃	M₁
T₀	Ⅰ	ⅢA	ⅢB	ⅣA	ⅣB
Tis	Ⅰ	ⅢA	ⅢB	ⅣA	ⅣB
T₁	Ⅰ	ⅢA	ⅢB	ⅣA	ⅣB
T₂	Ⅰ	ⅢA	ⅢB	ⅣA	ⅣB
T₃	Ⅱ	ⅢB	ⅢB	ⅣA	ⅣB
T_4a	ⅢB	ⅣA	ⅣA	ⅣA	ⅣB
T_4b	ⅣA	ⅣA	ⅣA	ⅣA	ⅣB

			N₀		N₁	N₂	N₃	M₁
			下段	上/中段	N₁	N₂	N₃	M₁
Tis		0
T_1a	G1		ⅠA		ⅡB	ⅢA	ⅣA	ⅣB
	G2-3		ⅠB
T_1b			ⅠB		ⅡB	ⅢA	ⅣA	ⅣB
T₂	G1		ⅠB		ⅢA	ⅢB	ⅣA	ⅣB
	G2-3		ⅡA
T₃	G1		ⅡA		ⅢB	ⅢB	ⅣA	ⅣB
	G2-3		ⅡA ⅡB
T_4a			ⅢB		ⅢB	ⅣA	ⅣA	ⅣB
T_4b			ⅣA		ⅣA	ⅣA	ⅣA	ⅣB

			N₀	N₁	N₂	N₃	M₁
Tis		0
	G1		ⅠA
T_1a	G2		ⅠB	ⅡB	ⅢA	ⅣA	ⅣB
	G3		ⅠC
	G1		ⅠB
T_1b	G2			ⅡB	ⅢA	ⅣA	ⅣB
	G3		ⅠC
	G1		ⅠC
T₂	G2			ⅢA	ⅢB	ⅣA	ⅣB
	G3		ⅡA
T₃			ⅡB	ⅢB	ⅢB	ⅣA	ⅣB
T_4a			ⅢB	ⅢB	ⅣA	ⅣA	ⅣB
T_4b			ⅣA	ⅣA	ⅣA	ⅣA	ⅣB

		N₀	N₁	N₂	N₃	M₁
Tis	0
T₁		Ⅰ	Ⅰ	Ⅲ	ⅣA	ⅣB
T₂		Ⅱ	Ⅱ	Ⅲ	ⅣA	ⅣB
T₃		Ⅱ	Ⅲ	Ⅲ	ⅣA	ⅣB
T_4a		ⅣA	ⅣA	ⅣA	ⅣA	ⅣB
T_4b		ⅣA	ⅣA	ⅣA	ⅣA	ⅣB

		N₀	N₁	N₂	N₃	M₁
Tis	0
T₁		Ⅰ	ⅡA	ⅣA	ⅣA	ⅣB
T₂		ⅡB	Ⅲ	ⅣA	ⅣA	ⅣB
T₃		Ⅲ	Ⅲ	ⅣA	ⅣA	ⅣB
T_4a		Ⅲ	Ⅲ	ⅣA	ⅣA	ⅣB
T_4b		ⅣA	ⅣA	ⅣA	ⅣA	ⅣB

RichHTML

PDF

Knowledge

Abstract

Cite this article

share this article

Figures/Tables 11

References 69

Related Articles 0

Recommended Articles

Metrics

Comments

诊断标准	肿瘤退缩分级
无存活癌细胞	0(完全反应)
单个或小簇癌细胞残留	1(中度反应)
残留癌灶伴间质纤维化	2(轻度反应)
少数或无肿瘤细胞消退;大量癌细胞残留	3(反应不良)

分级	体力状况
0	正常活动
1	症轻状,生活自理,能从事轻体力活动
2	能耐受肿瘤的症状,生活自理,但白天卧床时间不超过50%
3	症状严重,白天卧床时间超过50%,但还能起床站立,部分生活自理
4	病重,卧床不起,生活不能自理
5	死亡

评分	体力状况
100	正常,无症状和体征,无疾病证据
90	能正常活动,有轻微症状和体征
80	勉强可进行正常活动,有一些症状或体征
70	生活可自理,但不能维持正常生活或工作
60	生活能大部分自理,但偶尔需要别人帮助,不能从事正常工作
50	需要一定帮助和护理,以及给与药物治疗
40	生活不能自理,需要特别照顾和治疗
30	生活严重不能自理,有住院指征,尚不到病重
20	病重,完全失去自理能力,需要住院和积极的支持治疗
10	重危,临近死亡
0	死亡